Envoy Medical Inc [COCH] stock is trading at $1.50, up 4.17%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The COCH shares have gain 4.90% over the last week, with a monthly amount drifted -31.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Envoy Medical Inc [NASDAQ: COCH] stock has seen the most recent analyst activity on June 24, 2024, when Ascendiant Capital Markets initiated its Buy rating and assigned the stock a price target of $8.50.
Envoy Medical Inc [COCH] stock has fluctuated between $1.08 and $11.46 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Envoy Medical Inc [NASDAQ: COCH] shares were valued at $1.50 at the most recent close of the market. An investor can expect a potential return of 300.0% based on the average COCH price forecast.
Analyzing the COCH fundamentals
Envoy Medical Inc [NASDAQ:COCH] reported sales of 0.28M for the trailing twelve months, which represents a drop of -30.00%. Gross Profit Margin for this corporation currently stands at -2.12% with Operating Profit Margin at -77.22%, Pretax Profit Margin comes in at -75.75%, and Net Profit Margin reading is -75.75%. To continue investigating profitability, this company’s Return on Assets is posted at -2.24, Equity is 2.1 and Total Capital is -66.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.79.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3867 points at the first support level, and at 1.2733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5767, and for the 2nd resistance point, it is at 1.6533.
Ratios To Look Out For
For context, Envoy Medical Inc’s Current Ratio is 0.79. As well, the Quick Ratio is 0.61, while the Cash Ratio is 0.49. Considering the valuation of this stock, the price to sales ratio is 108.44.
Transactions by insiders
Recent insider trading involved Patel Mona Chetan, Director, that happened on Nov 20 ’24 when 2500.0 shares were purchased. Director, Patel Mona Chetan completed a deal on Sep 11 ’24 to buy 4000.0 shares. Meanwhile, Director Patel Mona Chetan bought 1000.0 shares on Sep 09 ’24.
